Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, ...

Abstract: Extremely large-scale multiple-input-multiple-output (XL-MIMO), which offers vast spatial degrees of freedom, has emerged as a potentially pivotal enabling technology for the sixth ...

Abstract: Unmanned aerial vehicles (UAVs) have found numerous applications and are expected to bring fertile business opportunities in the next decade. Among various enabling technologies for UAVs, ...

Novo Nordisk (NYSE:NVO) shares have moved little in recent sessions, with investors taking a wait-and-see approach. Market participants are weighing the company's recent performance metrics against ...

The owners of Novo Nordisk A/S and the Danish government are new anchor investors in what they say will become the world’s largest quantum venture fund, in a bid to boost Europe’s position in ...

After another dismal quarter for Novo Nordisk A/S shares, investors are looking to an experimental treatment of the most common form of dementia to help spark a revival. The Danish drugmaker is ...

Sept 30 (Reuters) - Telehealth firm LifeMD (LFMD.O), opens new tab said on Tuesday it would offer Danish drugmaker Novo Nordisk's (NOVOb.CO), opens new tab diabetes drug Ozempic at $499 per month to ...

Novo Nordisk may be breaking Heartseed's heart. As part of a company-wide restructuring under new CEO Maziar Mike Doustdar, the big pharma has axed a cell therapy collaboration with Heartseed worth ...

Danish pharmaceutical company Novo Nordisk, the maker of blockbuster drugs Ozempic and Wegovy, is planning job cuts at its Irish operation. The firm has not confirmed the number of planned layoffs but ...

In this market, three things make fundraising easier for a biotech: a derisked asset touting a well-defined profile and an experienced team to guide the program’s development. Crystalys Therapeutics ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

As India grapples with a surge in lifestyle-related illnesses, the approval of Ozempic marks more than just a new diabetes drug; it signals a shift toward modernising chronic disease care. Calling it ...